MACUGEN
Total Payments
$84,414
Transactions
60
Doctors
36
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $325.68 | 8 | 8 |
| 2018 | $39,285 | 28 | 19 |
| 2017 | $44,803 | 24 | 17 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $57,600 | 6 | 68.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $20,000 | 2 | 23.7% |
| Consulting Fee | $5,845 | 7 | 6.9% |
| Food and Beverage | $969.61 | 45 | 1.1% |
Payments by Type
Research
$57,600
6 transactions
General
$26,815
54 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE IV, OPEN LABEL, MULTI-CENTER STUDY TO ASSESS THE EFFECT OF INTRAVITREAL INJECTIONS OF MACUGEN PEGAPTANIB SODIUM INJECTION ADMINISTERED EVERY 6 WEEKS FOR 48 WEEKS ON THE CORNEAL ENDOTHELIUM | Bausch Health US, LLC | $28,897 | 1 |
| A PHASE IV, OPEN LABEL, MULTI-CENTER STUDY TO ASSESS THE EFFECT OF INTRAVITREAL INJECTIONS OF MACUGEN PEGAPTANIB SODIUM INJECTION ADMINISTERED EVERY 6 WEEKS FOR 48 WEEKS ON THE CORNEAL ENDOTHELIUM | Valeant Pharmaceuticals North America LLC | $28,703 | 3 |
Top Doctors Receiving Payments for MACUGEN — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Ophthalmology | Lynchburg, VA | $15.41 | 1 |
| , M.D | Ophthalmology | Lynchburg, VA | $15.41 | 1 |
| , MD | Ophthalmology | Philadelphia, PA | $14.71 | 1 |
| , M.D | Retina Specialist | Fort Worth, TX | $13.90 | 1 |
| , M.D | Ophthalmology | Fort Worth, TX | $13.90 | 1 |
| , M.D | Ophthalmology | Lawrenceville, NJ | $13.12 | 1 |
| , M.D | Ophthalmology | West Plains, MO | $12.74 | 1 |
| , OD | Optometrist | Philadelphia, PA | $12.03 | 1 |
| , M.D | Ophthalmology | Seattle, WA | $10.35 | 1 |
| Dana Deupree | — | Clearwater, FL | $9.14 | 1 |
| , M.D | Student in an Organized Health Care Education/Training Program | Miami, FL | $7.14 | 2 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $84,414
- Total Doctors 36
- Transactions 60
About MACUGEN
MACUGEN is a drug associated with $84,414 in payments to 36 healthcare providers, recorded across 60 transactions in the CMS Open Payments database. The primary manufacturer is Valeant Pharmaceuticals North America LLC.
Payment data is available from 2017 to 2019. In 2019, $325.68 was paid across 8 transactions to 8 doctors.
The most common payment nature for MACUGEN is "Unspecified" ($57,600, 68.2% of total).
MACUGEN is associated with 2 research studies, including "A PHASE IV, OPEN LABEL, MULTI-CENTER STUDY TO ASSESS THE EFFECT OF INTRAVITREAL INJECTIONS OF MACUGEN PEGAPTANIB SODIUM INJECTION ADMINISTERED EVERY 6 WEEKS FOR 48 WEEKS ON THE CORNEAL ENDOTHELIUM" ($28,897).